FDA Ends Tirzepatide Shortage, Orders Compounded Versions Phased Out by March 2024
The Food and Drug Administration (FDA) confirmed Thursday that Eli Lilly’s tirzepatide-based medications, Zepbound and Mounjaro, are no longer in shortage. This decision requires compounding pharmacies to cease production of alternative versions